ClinConnect ClinConnect Logo
Search / Trial NCT00825630

13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)

Launched by MERIDIAN BIOSCIENCE, INC. · Jan 20, 2009

Trial Information

Current as of June 25, 2025

Completed

Keywords

Hp Ubt Ppi

ClinConnect Summary

Adult subjects with suspected H pylori infection will be recruited and will undergo a 13C -Urea breath test (including citrica) with the BreathID test device. Those were found positive will undergo selected PPI treatment for 14 days and after 24 or 72 hours from the completion of the two weeks, will undergo a second breath test. Those found to be negative (false negative), will undergo additional breath tests.

* Those subjects that underwent any antibiotic, bismuth or PPI therapy 4 weeks prior to the trial, are to be excluded.
* Furthermore, pregnant or nursing women and subjects with an a...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adults with H.pylori infection.
  • Exclusion Criteria:
  • Pregnancy,
  • Nursing,
  • Antibiotic, bismuth or PPI treatment 2 weeks prior to trial,
  • Known sensitivity to Urea or citrica.

About Meridian Bioscience, Inc.

Meridian Bioscience, Inc. is a leading global biotechnology company focused on the development and commercialization of innovative diagnostic products and solutions for infectious diseases, gastrointestinal disorders, and other critical health conditions. With a commitment to advancing patient care, Meridian Bioscience leverages cutting-edge technologies and extensive expertise in molecular diagnostics, immunoassays, and life science research. The company's mission is to enhance diagnostic accuracy and efficiency, ultimately improving clinical outcomes and public health. Through rigorous clinical trials and partnerships, Meridian Bioscience aims to deliver reliable and timely diagnostic tools that empower healthcare professionals and patients alike.

Locations

Petah Tikva, , Israel

Petah Tikva, , Israel

Patients applied

0 patients applied

Trial Officials

Haim Shirin, MD

Principal Investigator

Sharon Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials